TPST Company Profile and Key Details

TPST has shown weak momentum, losing -9.79% over the past week and -74.56% over the past quarter, though year-to-date performance is down -10.1%. Short-term trend indicators are bullishly aligned (SMA20 -5.0%, SMA50 -14.87%, SMA200 -65.88%). The stock’s 14-day RSI is 38.0 (weak momentum), while the ATR of 0.19 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -81.28% below its high and over 8.02% above its low. Average 10-day trading volume of 198.57 thousand shares is slightly above the 3-month average of 171.27 thousand, indicating heightened recent market interest.

Tempest Therapeutics, Inc. has 4.44 million shares outstanding. The public float is 3.89 million shares, elevated short interest at 4.10% of float. This equals 181.85 thousand shares. The short ratio is 2.17 days. Institutional investors hold 45.51% of the float. Insiders own 35.37%. Westphal Christoph H holds 3.82 million shares, Longwood Fund, L.P. has 3.82 million shares and Woiwode Thomas has 2.12 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Tempest Therapeutics, Inc. generated EPS of -$10.10 over the past year. Five-year average earnings growth is 50.16%. Wall Street analysts project EPS growth of 51.1% annually over the next five years. The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$0.62. Next year's EPS is expected at $32.99. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $11.00 to $11.00. The high target offers 452.76% upside. The low target suggests 452.76% downside. The mean target is $11.00. This offers 452.76% upside. Tempest Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 0.0%. The prior quarter beat by -75.82%. Over the last six quarters, Apple has recorded several small beats. These include 10.81% in November 12, 2024.

Tempest Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.10. This means the shares are trading below this model’s fair value.

Tempest Therapeutics, Inc. (NASDAQ:TPST) closed at $2.04 USD, gaining $0.05 (2.51%) from the previous close of $1.99. The stock is currently mid-range between its 52-week high and low $1.50 and $12.23. With a market capitalization of about $9.06 million, Tempest Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.89). Key stats such as the average daily volume over the past year has been around 213.59 thousand shares, in line with its 52-week average. Headquartered in Brisbane, CA, Tempest Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Matthew Angel, the company employs approximately 24 people and listed since November 12, 2012. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer.

Tempest Therapeutics, Inc. (NASDAQ:TPST) shares are down -10.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tempest Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.32. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $26.90, suggesting 1251.76% upside. Our AI forecast model points to short-term weakness (-10.55% over two weeks), a medium-term fall (-44.22% over three months), and a longer-term loss (-80.4% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Tempest Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.55%, with price expected at $1.78 by May 14, 2026, within a range of $1.49 to $2.08 3-Month Outlook: Projected fall of -44.22%, reaching $1.11 by July 29, 2026, with a range of $0.76 to $1.47. 1-Year Outlook: Projected loss of -80.4%, with price at $0.39 by April 30, 2027, within a range of $0.00 to $2.30.

Tempest Therapeutics, Inc. trades at a P/E ratio of -0.32, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.24 suggesting the stock is closer to book value. The P/FCF stands at -0.19, also above market averages.